TNDMTANDEM DIABETES CARE INC
Surgical & Medical Instruments & Apparatus
- Revenue
- $1.0B
- 7.9% YoY
- Operating margin
- -18.5%
- 75% YoY
- EBITDA
- −$170M
- 106% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $20M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear9% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $703M | $801M | $748M | $940M | $1.0B | 7.9% |
| Operating income | $23M | −$93M | −$233M | −$99M | −$187M | 89% |
| Net income | $16M | −$95M | −$223M | −$96M | −$205M | 113% |
| Operating cash flow | $111M | $50M | −$32M | $24M | −$10M | 140% |
| Capex | $14M | $34M | $27M | $19M | $20M | 3.7% |
| Stock-based comp | $61M | $85M | $88M | $101M | $92M | 8.9% |
| Buybacks | — | $0 | $0 | $30M | $0 | 100% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $33K · 2
- Net
- −$33K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $3M | 23 | 99 |
| FY2024 | $9M | $7M | 60 | 105 |
| FY2023 | $5M | $2M | 50 | 106 |
| FY2022 | $6M | −$8M | 75 | 100 |
| FY2021 | $6M | $16M | 253 | 125 |